News

Under the terms of the agreement, CASI has obtained global rights to TSK011010 for an upfront payment of 5 million euros and an equity investment of 2 million

DUAKLIR PRESSAIR is a fixed-dose LAMA/LABA combination of the long-acting muscarinic antagonist (LAMA) aclidinium and the long-acting beta agonist (LABA) formoterol. It is administered twice daily via the

As per terms of the deal, twoXAR will apply its AI discovery technology to identify a set of initial candidates to treat lung cancer through novel biological mechanisms

LabCorp said that the proposed deals will make the company to pay a net cash of $485m and will add an incremental $156m to revenues on a pro

The research collaboration is part of Atomwise’s Artificial Intelligence Molecular Screen (AIMS) Awards program. The Centers for Disease Control and Prevention (CDC) estimates that 6-7 million people in

Hyleukin-7 also received ODD from the European Medicines Agency in 2017, and it is the first and only agent that has obtained ODD for ICL. ICL was first

Based in Athens of Greece, Genepharm is involved in the development, manufacturing and out-licensing of high-value generic pharmaceutical products. The company, which owns a wide portfolio of products,

Under the three-year deal, the partnership will use insitro’s platform to create disease models for NASH and discover targets that can impact clinical progression and regression of the

iPSCs can be derived from adult human tissue cells yet share the developmental potentials of embryonic stem cells. Currently Japan has 6 ongoing clinical trials utilizing this technology,